Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Aasld

<< Previous

Bullboard Posts

Next >>

Post by qwerty22on Nov 17, 2020 10:48am

856 Views

Post# 31914037

Aasld

Thought this was a good summary of the highlights of aasld so sharing. Crazy how Loomba is at the center of so much.
https://www.hepmag.com/article/pipeline-nafld-nash-treatment

This one is super intriguing given tesamorelin's history. I don't expect it changes any paradigms but maybe it's something to think about when Ph4s roll around.
https://www.newswise.com/articles/high-abdominal-fat-and-low-liver-fat-combo-increases-coronary-heart-disease-risk
It is intriguing maybe given some of the secondary measurements THTX might make during the Ph3. It strikes me that mdgl see what their drug is capable of and then shift the discussion towards that. Thtx could think about doing something similar.

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide